RWLK REWALK ROBOTICS LTD

Lifeward to Report First Quarter 2025 Financial Results on May 15, 2025

Lifeward to Report First Quarter 2025 Financial Results on May 15, 2025

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a  global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its first quarter 2025 financial results before the markets open on Thursday, May 15, 2025.

Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following:

Toll free (U.S.)1-833-316-0561
International (U.S)1-412-317-0690
Germany0800-6647650
Israel1-80-9212373
Access CodePlease reference the “Lifeward Earnings Call”
  

The conference call will be webcast live and the webcast can be accessed through a link on the Company’s website at  in the "Investors" section, or through the following link: . An archived webcast will also be available on the company's website.

About Lifeward

Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity system, the MyoCycle FES System, and the ReStore Exo-Suit.

Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit .

Lifeward®, ReWalk®, ReStore® and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.   

Lifeward Media Relations:

Kathleen O’Donnell

Vice President, Marketing & New Business Development

Lifeward Ltd.

E:

Lifeward Investor Contact:

Mike Lawless

Chief Financial Officer

Lifeward Ltd.

E: 



EN
07/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on REWALK ROBOTICS LTD

 PRESS RELEASE

Lifeward Completes Research Program with Israeli Human-Robot Interacti...

Lifeward Completes Research Program with Israeli Human-Robot Interaction Consortium to Integrate Artificial Intelligence and Exoskeletons Three-year program examined opportunities to integrate artificial intelligence technology into future generations of ReWalk Exoskeletons MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced the Company has completed its research prog...

 PRESS RELEASE

Lifeward to Report First Quarter 2025 Financial Results on May 15, 202...

Lifeward to Report First Quarter 2025 Financial Results on May 15, 2025 MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a  global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its first quarter 2025 financial results before the markets open on Thursday, May 15, 2025. Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will host a conference call and liv...

 PRESS RELEASE

First Major U.S. Commercial Health Insurer Approves Purchase of ReWalk...

First Major U.S. Commercial Health Insurer Approves Purchase of ReWalk 7 Personal Exoskeleton Approval signals important progress in U.S. market expansion as major commercial health insurers begin to follow precedent set with Medicare reimbursement for personal exoskeletons established in 2024 Decision to cover device arrives shortly after the launch of the ReWalk 7 Personal Exoskeleton, which was released for sales in the U.S. earlier this month MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company...

 PRESS RELEASE

Paralyzed Israeli Soldier Walks Again with Use of the ReWalk Personal ...

Paralyzed Israeli Soldier Walks Again with Use of the ReWalk Personal Exoskeleton Cooperation between Lifeward and Beilinson Hospital marks the first step towards a national policy in Israel on Exoskeleton training and procurement MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 24, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that an Israeli soldier wounded in the current war has completed training and h...

 PRESS RELEASE

Lifeward Launches Sales of the ReWalk 7 Personal Exoskeleton in U.S. M...

Lifeward Launches Sales of the ReWalk 7 Personal Exoskeleton in U.S. Market MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 15, 2025 (GLOBE NEWSWIRE) -- Seventh generation of industry-leading personal exoskeleton is now available nationwide for individuals with spinal cord injury New and improved features streamline user experience for greater control, engagement, and confidence during walking in everyday environments Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitation...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch